NeuroSense Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 46.9%.

Top 19 shareholders own 29.38% of the company

Ownership	Name	Shares	Current Value	Change %	Portfolio %
17.8%	Alon Ben-Noon	3,081,600	US$4.2m	1.48%	no data
5.97%	Ariel Gordon	1,034,607	US$1.4m	0.13%	no data
2.65%	Or Eisenberg	460,008	US$621.0k	103%	no data
0.71%	Ferenc Tracik	122,951	US$166.0k	173%	no data
0.55%	Meitav Investment House Ltd	95,000	US$128.2k	0%	no data
0.38%	Niva Russek-Blum	65,428	US$88.3k	0%	no data
0.37%	Mark Leuchtenberger	64,000	US$86.4k	-11.1%	no data
0.16%	Revital Mandil-Levin	28,526	US$38.5k	0.19%	no data
0.14%	Caren Deardorf	24,000	US$32.4k	-20%	no data
0.14%	Christine Pellizzari	24,000	US$32.4k	0%	no data
0.14%	Cary Claiborne	24,000	US$32.4k	0%	no data
0.13%	Hagit Binder	22,000	US$29.7k	0%	no data
0.081%	Hudson River Trading LLC, Asset Management Arm	13,998	US$18.9k	0%	no data
0.073%	Scientech Research LLC	12,584	US$17.0k	0%	0.02%
0.069%	Geode Capital Management, LLC	11,963	US$16.1k	0%	no data
0.032%	UBS Asset Management AG	5,496	US$7.4k	-43.1%	no data
0.0086%	Morgan Stanley, Investment Banking and Brokerage Investments	1,500	US$2.0k	0%	no data
0.0058%	Carson Wealth Management Group	1,000	US$1.4k	0%	no data
0.00031%	Qube Research & Technologies Ltd	54	US$72.5	0%	no data